Recent Research Analysts’ Ratings Updates for Hologic (HOLX)

A number of research firms have changed their ratings and price targets for Hologic (NASDAQ: HOLX):

• 11/14/2024 – Hologic was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 11/6/2024 – Hologic was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/5/2024 – Hologic had its price target raised by analysts at Royal Bank of Canada from $86.00 to $89.00. They now have a “sector perform” rating on the stock.
• 11/5/2024 – Hologic had its price target raised by analysts at JPMorgan Chase & Co. from $92.00 to $94.00. They now have an “overweight” rating on the stock.
• 11/5/2024 – Hologic had its price target lowered by analysts at Mizuho from $90.00 to $87.00. They now have an “outperform” rating on the stock.
• 11/5/2024 – Hologic had its price target raised by analysts at Raymond James from $93.00 to $95.00. They now have an “outperform” rating on the stock.
• 11/5/2024 – Hologic had its price target raised by analysts at UBS Group AG from $84.00 to $90.00. They now have a “neutral” rating on the stock.
• 10/15/2024 – Hologic had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $90.00 price target on the stock.
• 10/8/2024 – Hologic had its price target lowered by analysts at Leerink Partners from $95.00 to $90.00. They now have an “outperform” rating on the stock.
• 10/4/2024 – Hologic had its price target raised by analysts at Mizuho from $85.00 to $90.00. They now have an “outperform” rating on the stock.
• 10/1/2024 – Hologic was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $85.00 price target on the stock, down previously from $95.00.
• 10/1/2024 – Hologic had its price target raised by analysts at Evercore ISI from $78.00 to $82.00. They now have an “in-line” rating on the stock.
• 9/27/2024 – Hologic was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.

Hologic Price Performance

HOLX stock traded down $0.73 during trading on Tuesday, hitting $79.00. The company had a trading volume of 1,922,089 shares, compared to its average volume of 1,595,139. The company has a fifty day moving average price of $80.38 and a two-hundred day moving average price of $78.38. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a fifty-two week low of $67.59 and a fifty-two week high of $84.67. The company has a market cap of $18.35 billion, a P/E ratio of 23.72, a P/E/G ratio of 2.49 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.89 earnings per share. Equities research analysts expect that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Institutional Trading of Hologic

A number of institutional investors have recently bought and sold shares of the business. Innealta Capital LLC bought a new stake in Hologic during the 2nd quarter worth about $25,000. Wolff Wiese Magana LLC acquired a new stake in Hologic during the 3rd quarter worth approximately $25,000. Groupama Asset Managment boosted its position in shares of Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 2,999 shares during the period. iA Global Asset Management Inc. bought a new stake in Hologic in the 1st quarter valued at about $37,000. Finally, Sunbelt Securities Inc. acquired a new stake in Hologic during the second quarter worth approximately $37,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.